NO20004664L - FremgangsmÕte for fremstilling av HIV proteaseinhibitorer - Google Patents

FremgangsmÕte for fremstilling av HIV proteaseinhibitorer

Info

Publication number
NO20004664L
NO20004664L NO20004664A NO20004664A NO20004664L NO 20004664 L NO20004664 L NO 20004664L NO 20004664 A NO20004664 A NO 20004664A NO 20004664 A NO20004664 A NO 20004664A NO 20004664 L NO20004664 L NO 20004664L
Authority
NO
Norway
Prior art keywords
preparation
protease inhibitors
hiv protease
hiv
inhibitors
Prior art date
Application number
NO20004664A
Other languages
English (en)
Other versions
NO20004664D0 (no
NO317648B1 (no
Inventor
Stephen Mcghie
Stephen Rout
Hardev Sinhgh
David D Deininger
Emile Al-Farhan
John Mark O'callaghan
Mark Stuart Robertson
Keith Rodgers
Roger Dennis Tung
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20004664D0 publication Critical patent/NO20004664D0/no
Publication of NO20004664L publication Critical patent/NO20004664L/no
Publication of NO317648B1 publication Critical patent/NO317648B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20004664A 1998-03-20 2000-09-19 Fremgangsmate for fremstilling av HIV proteaseinhibitorer NO317648B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors
PCT/GB1999/000852 WO1999048885A1 (en) 1998-03-20 1999-03-18 Process for the synthesis of hiv protease inhibitors

Publications (3)

Publication Number Publication Date
NO20004664D0 NO20004664D0 (no) 2000-09-19
NO20004664L true NO20004664L (no) 2000-09-19
NO317648B1 NO317648B1 (no) 2004-11-29

Family

ID=10828884

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004664A NO317648B1 (no) 1998-03-20 2000-09-19 Fremgangsmate for fremstilling av HIV proteaseinhibitorer

Country Status (31)

Country Link
US (1) US6281367B1 (no)
EP (1) EP1066276B1 (no)
JP (1) JP3363439B2 (no)
KR (1) KR100555278B1 (no)
CN (1) CN1308319C (no)
AP (1) AP1226A (no)
AT (1) ATE242772T1 (no)
AU (1) AU751534B2 (no)
BR (1) BR9908970A (no)
CA (1) CA2324217C (no)
CZ (1) CZ299193B6 (no)
DE (1) DE69908761T2 (no)
DK (1) DK1066276T3 (no)
EA (1) EA003022B1 (no)
EE (1) EE04750B1 (no)
ES (1) ES2203090T3 (no)
GB (1) GB9805898D0 (no)
HR (1) HRP20000609B1 (no)
HU (1) HUP0105439A3 (no)
ID (1) ID26587A (no)
IL (1) IL138127A (no)
IS (1) IS2273B (no)
NO (1) NO317648B1 (no)
NZ (1) NZ506563A (no)
PL (1) PL201810B1 (no)
PT (1) PT1066276E (no)
RS (1) RS49954B (no)
SK (1) SK283939B6 (no)
TR (1) TR200002698T2 (no)
WO (1) WO1999048885A1 (no)
ZA (1) ZA200004482B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
EP2314563A3 (en) * 1999-12-23 2012-04-04 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
PT1725566E (pt) * 2003-12-23 2009-09-16 Tibotec Pharm Ltd Processo para a preparação de (1s,2r)-3-[[(4-aminofenil) sulfonil](isobutil)amino]-1-benzil-2-hidroxipropilcarbamato de (3r,3as,6ar)-hexa-hidrofuro[2,3-b]furan-3-ilo
JP4818124B2 (ja) * 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド （３Ｒ，３ａＳ，６ａＲ）−ヘキサヒドロフロ〔２，３−ｂ〕フラン−３−イル（１Ｓ，１Ｒ）−３−〔〔（４−アミノフェニル）スルホニル〕（イソブチル）アミノ〕−１−ベンジル−２−ヒドロキシプロピルカルバマートの製造方法
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
EP2614055A2 (en) 2010-09-10 2013-07-17 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
ES2123065T3 (es) * 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða

Also Published As

Publication number Publication date
NO20004664D0 (no) 2000-09-19
SK13732000A3 (sk) 2001-08-06
DK1066276T3 (da) 2003-10-06
CN1293668A (zh) 2001-05-02
AU2947599A (en) 1999-10-18
ID26587A (id) 2001-01-18
AU751534B2 (en) 2002-08-22
DE69908761D1 (de) 2003-07-17
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
NZ506563A (en) 2003-05-30
PL201810B1 (pl) 2009-05-29
NO317648B1 (no) 2004-11-29
AP2000001911A0 (en) 2000-09-30
SK283939B6 (sk) 2004-05-04
KR100555278B1 (ko) 2006-03-03
DE69908761T2 (de) 2004-02-19
EP1066276A1 (en) 2001-01-10
CZ20003457A3 (cs) 2001-04-11
RS49954B (sr) 2008-09-29
EE200000568A (et) 2002-02-15
BR9908970A (pt) 2000-11-28
ES2203090T3 (es) 2004-04-01
HRP20000609A2 (en) 2001-04-30
KR20010042022A (ko) 2001-05-25
IS2273B (is) 2007-07-15
EE04750B1 (et) 2006-12-15
HUP0105439A2 (en) 2002-06-29
CN1308319C (zh) 2007-04-04
EA003022B1 (ru) 2002-12-26
EA200000859A1 (ru) 2001-04-23
AP1226A (en) 2003-11-21
JP3363439B2 (ja) 2003-01-08
PT1066276E (pt) 2003-10-31
JP2002507609A (ja) 2002-03-12
HRP20000609B1 (en) 2006-05-31
IS5605A (is) 2000-08-29
ZA200004482B (en) 2001-11-28
TR200002698T2 (tr) 2000-12-21
IL138127A (en) 2003-10-31
PL342602A1 (en) 2001-06-18
ATE242772T1 (de) 2003-06-15
WO1999048885A1 (en) 1999-09-30
EP1066276B1 (en) 2003-06-11
YU55900A (sh) 2003-02-28
HK1032047A1 (en) 2001-07-06
GB9805898D0 (en) 1998-05-13
CZ299193B6 (cs) 2008-05-14
CA2324217C (en) 2008-02-19
US6281367B1 (en) 2001-08-28
CA2324217A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
DK1085981T3 (da) Fremgangsmåde til emballering
NO20012984D0 (no) Succinoylamino benzodiazepiner som inhibitorer av AB proteinproduksjon
NO990548L (no) Inhibitorer for cystein-protease
NO20003692L (no) Bisulfat-salt av HIV-protease-inhibitor
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20004219L (no) Inhibitorer av fosfolipaseenzymer
NO20004220L (no) Inhibitorer av fosfolipaseenzymer
NO20012980L (no) Proteaseinhibitorer
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
PT1200231E (pt) Metodo de fabrico de ferramentas microabrasivas
DK1114051T3 (da) Inhibitorer for p38
ID26990A (id) Metode pembuatan dimetilnaftalena
NO20016034D0 (no) Inhibitorer av aspartylprotease
PT1150966E (pt) Metodo de preparacao de 5-cianoftalido
NO20004664D0 (no) FremgangsmÕte for fremstilling av HIV proteaseinhibitorer
FI20000553L (fi) Proteaasi-inhibiittoreina käyttökelpoisten 4-hydroksi-2-oksopyraanijohdannaisten valmistusmenetelmä
FI963054L (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
DK0987356T3 (da) Fremgangsmåde til trækning
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
FI20000325A0 (fi) Menetelmä rakenteen rasituksen määrittämiseksi
AU5089699A (en) Methods of making dihydropyrone hiv protease inhibitors
EE9900109A (et) Vaheühendid HIV-proteaasi inhibiitorite valmistamiseks ja HIV-proteaasi inhibiitorite valmistamismeetodid
SE9802223D0 (sv) Method of application
SE9803550D0 (sv) Method of application
UA25626A (uk) Спосіб виготовлеhhя пива

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees